Spadel SA produces and markets natural mineral water in Belgium. It offers natural mineral and flavored water, including still and sparkling, as well as lemonades. The company provides its products under the Spa, Bru, Wa…
Industry Peers
Beverages - Non-Alcoholic| Headline | Source | Time |
|---|---|---|
Yesterday | ||
DDHnet | ||
Older | ||
LLa Libre.be | ||
SSudinfo | ||
Unveiling Three Undiscovered Gems in Europe with Strong Potential As the pan-European STOXX Europe 600 Index remains broadly flat amid geopolitical tensions and fluctuating energy prices, investors are keenly observing the earnings momentum that is beginning to surface across various sectors. In this context, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as economic sentiment in the eurozone reaches its lowest level since 2020. | ||
FForbes Belgique | ||
RRetailDetail BE | ||
LLa Libre.be | ||
Spadel And 2 Other Promising Small Caps with Solid Potential As the pan-European STOXX Europe 600 Index shows modest gains amid a backdrop of economic optimism and geopolitical concerns, small-cap stocks in Europe are drawing attention for their potential resilience and growth opportunities. In this environment, identifying promising small caps like Spadel requires a focus on solid fundamentals and strategic positioning within their respective industries. | ||
Undiscovered European Stock Gems to Explore in January 2026 As the pan-European STOXX Europe 600 Index reaches new highs and closes out 2025 with its strongest yearly performance since 2021, investors are increasingly turning their attention to the region's promising small-cap landscape. In this buoyant economic environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding for those looking to explore undiscovered gems in Europe's dynamic market. | ||
Undiscovered Gems in Europe Top Stocks for December 2025 As European markets continue to show resilience, with the STOXX Europe 600 Index climbing 2.35% and major single-country indexes like Germany's DAX and the UK's FTSE 100 also posting gains, investors are increasingly interested in small-cap stocks that may offer unique opportunities amid subdued inflation rates and recent economic developments. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding for those looking to uncover... | ||
Undiscovered Gems in Europe with Promising Potential This November 2025 As the European market navigates a mixed landscape with the pan-European STOXX Europe 600 Index recently pulling back after reaching new highs, investors are keenly observing how economic indicators like inflation and GDP growth might influence future monetary policy decisions by the European Central Bank. In this context of cautious optimism, identifying stocks that demonstrate resilience and potential for growth amidst these broader economic trends can be particularly rewarding for those... | ||
Exploring October 2025's Undiscovered Gems in Europe As the pan-European STOXX Europe 600 Index remains relatively stable amidst ongoing assessments of interest rate policies and trade tensions, major indices like Italy's FTSE MIB and Germany's DAX have shown modest gains, reflecting a cautiously optimistic market sentiment. In this environment, identifying potential growth opportunities requires a keen eye for stocks that not only demonstrate resilience but also possess the ability to capitalize on emerging economic trends. | ||
Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
Spadel And 2 Other European Small Caps With Strong Financials As European markets experience a positive upswing, with the STOXX Europe 600 Index rising by 1.40% amid hopes of lower U.S. borrowing costs, investors are increasingly looking towards small-cap stocks as potential opportunities for growth. In this environment, identifying companies with strong financials and robust business activity can be crucial for those seeking to navigate the evolving economic landscape effectively. | ||